COVID-19 Serology Data Provide Guidance for Future Deployments of Convalescent Plasma
mBio · 2023
DOI: 10.1128/mbio.00428-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, 2023. Verfasst von David Sullivan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Microbiology, Johns Hopkins School of Public Health, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Measurement of antibody content and function after a viral illness is important for diagnosis and selection of the best convalescent plasma (CP) units for passive immunization. Zhang et al. (mBio 14:e03523-22, 2013, https://doi.org/10.1128/mbio.03523-22 ) analyzed over 19,000 coronavirus disease 2019 (COVID-19) CP (CCP) samples from the early days of the COVID-19 pandemic and reported a moderately strong correlation between antibody amount and neutralizing titer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Microbiology, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.
ORCID-Profile: David Sullivan, Arturo Casadevall
Förderung
- NIAID NIH HHS
Zitieren
APA
Sullivan, D., & Casadevall, A. (2023). COVID-19 Serology Data Provide Guidance for Future Deployments of Convalescent Plasma. mBio. https://doi.org/10.1128/mbio.00428-23
Vancouver
Sullivan D, Casadevall A. COVID-19 Serology Data Provide Guidance for Future Deployments of Convalescent Plasma. mBio. 2023. doi:10.1128/mbio.00428-23
BibTeX
@article{Sullivan2023,
author = {Sullivan, David and Casadevall, Arturo},
title = {COVID-19 Serology Data Provide Guidance for Future Deployments of Convalescent Plasma},
journal = {mBio},
year = {2023},
doi = {10.1128/mbio.00428-23}
}
EUVIMED